APLN and coronary artery disorder: Additionally, in patients with different cardiovascular diseases, such as coronary artery disease, systolic left ventricular dysfunction disease, and left ventricular hypertrophy, apelin concentration is also altered, suggesting that apelin peptides could be successfully used as a biomarker of cardiovascular system pathologies.